Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety
profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).